The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.

Kenzo Takahashi, Yasushi Ohkusa, Jong-Young Kim
Author Information
  1. Kenzo Takahashi: Clinical Research Center Sanno Hospital, International University of Health and Welfare, 8-10-16 Akasaka, Tokyo, 107-0052, Japan. kt_intl_@ja2.so-net.ne.jp

Abstract

BACKGROUND: During 1999-2003, Japan experienced a series of measles epidemics, and in Action Plans to Control Measles and the Future Problems, it was proposed that infants be immunized soon after their one-year birthday.In this study, we attempted to estimate the nationwide economic disease burden of measles based on clinical data and the economic effectiveness of this proposal using the benefit cost ratio.
METHODS: Our survey target was measles patients treated at Chiba-Nishi general hospital from January 1999 to September 2001. Two hundred ninety-one cases were extracted from the database. The survey team composed of 3 pediatricians and 1 physician from Chiba-Nishi general hospital examined patient files and obtained additional information by telephone interview.We analyzed data based on a static model, which assumed that the number of measles patients would be zero after 100% coverage of single-antigen measles vaccine.Costs were defined as the direct cost for measles treatment, vaccination and transportation and the indirect cost of workdays lost due to the nursing of patients, hospital visits for vaccination or nursing due to adverse reactions. Benefits were defined as savings on direct and indirect costs. Based on these definitions, we estimated the nationwide costs of treatment and vaccination.
RESULTS: Using our static model, the nationwide total cost for measles treatment was estimated to be US$ 404 million, while the vaccination cost was US$165 million. The benefit cost ratio of the base case was 2.48 and ranged from 2.21 to 4.97 with sensitivity analysis.
CONCLUSIONS: Although the model has some limitations, we conclude that the policy of immunizing infants soon after their one-year birthday is economically effective.

References

  1. Kansenshogaku Zasshi. 2006 May;80(3):212-9 [PMID: 16780127]
  2. Lancet. 2004 Jul 24-30;364(9431):328-9 [PMID: 15276387]
  3. Vaccine. 1998 May-Jun;16(9-10):989-96 [PMID: 9682349]
  4. Vaccine. 1990 Mar;8 Suppl:S95-9 [PMID: 2139290]
  5. Jpn J Infect Dis. 2002 Aug;55(4):101-11 [PMID: 12403906]
  6. MMWR Morb Mortal Wkly Rep. 2008 Sep 26;57(38):1049-52 [PMID: 18818586]
  7. Med Decis Making. 2003 Jan-Feb;23(1):76-82 [PMID: 12583457]
  8. Dev Biol Stand. 1979;43:273-7 [PMID: 118067]
  9. Pediatrics. 2000 Nov;106(5):973-6 [PMID: 11061762]
  10. N Engl J Med. 1995 Oct 5;333(14):889-93 [PMID: 7666874]
  11. J Infect Dis. 2004 May 1;189 Suppl 1:S131-45 [PMID: 15106102]
  12. Scand J Soc Med. 1978;6(3):111-5 [PMID: 103198]
  13. J Infect Dis. 2011 Jul;204 Suppl 1:S107-15 [PMID: 21666151]
  14. J Infect Dis. 2011 Jul;204 Suppl 1:S28-34 [PMID: 21666174]
  15. N Engl J Med. 1988 Sep 22;319(12):807-12 [PMID: 3412412]
  16. Epidemiol Infect. 2003 Apr;130(2):273-83 [PMID: 12729196]
  17. BMC Public Health. 2005 Jun 04;5:59 [PMID: 15935101]
  18. Kansenshogaku Zasshi. 2005 Jan;79(1):7-12 [PMID: 15717477]
  19. Arch Intern Med. 2001 Mar 12;161(5):749-59 [PMID: 11231710]
  20. Vaccine. 2005 Mar 18;23(17-18):2256-60 [PMID: 15755606]

MeSH Term

Adolescent
Adult
Age Distribution
Child
Child, Preschool
Cost of Illness
Cost-Benefit Analysis
Databases, Factual
Female
Health Policy
Health Services Research
Humans
Infant
Japan
Male
Measles
Measles Vaccine
Models, Econometric
Retrospective Studies
Vaccination
Young Adult

Chemicals

Measles Vaccine

Word Cloud

Created with Highcharts 10.0.0measlescostvaccinationnationwideeconomicbenefitpatientshospitalmodeltreatmentJapaninfantssoonone-yearbirthdaystudydiseaseburdenbaseddataratiosurveyChiba-Nishigeneralstaticdefineddirectindirectduenursingcostsestimatedmillion2analysisBACKGROUND:1999-2003experiencedseriesepidemicsActionPlansControlMeaslesFutureProblemsproposedimmunizedInattemptedestimateclinicaleffectivenessproposalusingMETHODS:targettreatedJanuary1999September2001Twohundredninety-onecasesextracteddatabaseteamcomposed3pediatricians1physicianexaminedpatientfilesobtainedadditionalinformationtelephoneinterviewWeanalyzedassumednumberzero100%coveragesingle-antigenvaccineCoststransportationworkdayslostvisitsadversereactionsBenefitssavingsBaseddefinitionsRESULTS:UsingtotalUS$404US$165basecase48ranged21497sensitivityCONCLUSIONS:Althoughlimitationsconcludepolicyimmunizingeconomicallyeffectiveretrospective

Similar Articles

Cited By